TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25664905

Group type: EXPERIMENTAL
Intervention: i.v. ascorbate infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascorbate infusion plus oral H1/H2 histamine receptor blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: i.v. N-acetylcysteine infusion
Number of subjects: 0
Study: 25091379

Group type: COMPARATOR
Intervention: EPA+DHA supplementation (0, 300, 600, 900, or 1,800 mg/d)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Baseline RBC DHA levels
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Baseline arachidonic acid levels
Number of subjects: 116
Study: 22352981

Group type: EXPERIMENTAL
Intervention: Out-group praise with external attributions for success
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-group praise
Number of subjects: 0
Study: 18922525

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (0.1 mg bolus with further boluses every 5 minutes as required)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No tocolysis
Number of subjects: 114
Study: 17263636

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11487483

Group type: COMPARATOR
Intervention: Standard-dose intravenous immunoglobulin (adults: 300 mg/kg every 4 weeks; children: 400 mg/kg every 4 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (adults: 600 mg/kg every 4 weeks; children: 800 mg/kg every 4 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard-dose intravenous immunoglobulin
Number of subjects: 43
Study: 9610786

Group type: EXPERIMENTAL
Intervention: GGN repeat length of 23
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: GGN repeat length deviation from 23
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Mean GGN repeat length
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Spread of GGN repeat lengths
Number of subjects: 1376
Study: 8110553

Group type: EXPERIMENTAL
Intervention: Diamorphine-bupivacaine mixture (0.0625% plain bupivacaine 6.25 mg h‐1 mixed with 0.005% diamorphine 0.5 mg h‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (0.125% plain bupivacaine 12.5 mg h‐1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diamorphine-bupivacaine mixture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 3074294

Group type: EXPERIMENTAL
Intervention: NovoPen II
Number of subjects: 19

Group type: COMPARATOR
Intervention: Insulin Protaphane HM in Penfill
Number of subjects: 19
Study: 31286736

Group type: EXPERIMENTAL
Intervention: 3-moxa-cone group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5-moxa-cone group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 7-moxa-cone group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham-moxibustion group
Number of subjects: 120
Study: 28668857

Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study: 26176956

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (n=529)
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Open surgery (n=528)
Number of subjects: 1767
Study: 23212859

Group type: EXPERIMENTAL
Intervention: Early start dialysis (eGFR 10 ‐ 14 mL/min/1.73 m²)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Late start dialysis (eGFR 5 ‐ 7 mL/min/1.73 m²)
Number of subjects: 466
Study: 20202983

Group type: EXPERIMENTAL
Intervention: PES+ group (inducible ventricular arrhythmias)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PES- group (non-inducible ventricular arrhythmias)
Number of subjects: 30
Study: 17453746

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: All beta-blockers
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 5
Study: 15565481

Group type: EXPERIMENTAL
Intervention: Strict protocol of care for EVD insertion, nursing, and surveillance
Number of subjects: 306
Study: 12176787

Group type: EXPERIMENTAL
Intervention: 3-week schedule of gemcitabine (1000 mg/m2 on days 1 and 8 of a 21-day cycle)
Number of subjects: 107

Group type: COMPARATOR
Intervention: 4-week schedule of gemcitabine (1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle)
Number of subjects: 107

Group type: COMPARATOR
Intervention: 4-week schedule of gemcitabine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 3-week schedule of gemcitabine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both regimens (3-week and 4-week schedules)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 3-week schedule
Number of subjects: 107

Group type: COMPARATOR
Intervention: 4-week schedule
Number of subjects: 107
Study: 10210549

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with paclitaxel plus carboplatin
Number of subjects: 38
Study: 8582541

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise training programme at 50-70% maximal effort for 3 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise training programme
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 2203255

Group type: EXPERIMENTAL
Intervention: 90 mL tap water ingested over 10 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 90 mL tap water ingested over 30 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mL tap water ingested over 10 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mL tap water ingested over 30 min
Number of subjects: 10
Study: 867453

Group type: EXPERIMENTAL
Intervention: Local anesthesia during outpatient vacuum aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overnight postabortion observation
Number of subjects: 0
Study: 31102834

Group type: EXPERIMENTAL
Intervention: CSPAP implementation
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Systematic observation, accelerometers, and questionnaires
Number of subjects: 2642
Study: 30096704

Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg every 2 or 3 weeks for 24 months
Number of subjects: 833

Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg every 3 weeks for four doses
Number of subjects: 833
Study: 26823338

Group type: EXPERIMENTAL
Intervention: Measles-Rubella Vaccine + Human Rotavirus Vaccine (MR + HRV)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Measles-Rubella Vaccine (MR)
Number of subjects: 480
Study: 25268365

Group type: EXPERIMENTAL
Intervention: High intensity endurance and strength exercise (12 weeks)
Number of subjects: 28
Study: 22770867

Group type: EXPERIMENTAL
Intervention: Nasal gel administered using a radial-hole inhaler
Number of subjects: 16

Group type: COMPARATOR
Intervention: Different administration methods
Number of subjects: 16
Study: 19913325

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with carboplatin (AUC=5) and docetaxel (75mg/m2) every 3 weeks for four cycles, initiated 1-4 weeks post-surgery, with prophylactic G-CSF supportive therapy.
Number of subjects: 80
Study: 18029115

Group type: EXPERIMENTAL
Intervention: SRPHK1 outcome measure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine toxicology measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined measure (SRPHK1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concordance between self-report and urine toxicology
Number of subjects: 0
Study: 16118293

Group type: EXPERIMENTAL
Intervention: Stair climbing (n = 8), progressively increased from 1 ascent/day in week 1 to 5 ascents/day in weeks 7 and 8, 5 days a week, at a stepping rate of 90 steps/minute
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stair climbing (n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 15
Study: 11978748

Group type: EXPERIMENTAL
Intervention: Oligosaccharide supplemented formula (10 g/l)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (maltodextrin supplemented formula)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reference group (fortified mother's milk)
Number of subjects: 15
Study: 9988877

Group type: EXPERIMENTAL
Intervention: High dose of vitamin A (50,000 IU per day, median; range 10,000-300,000 IU per day)
Number of subjects: 423

Group type: COMPARATOR
Intervention: High vitamin A exposure later in pregnancy (control group 1)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Nonteratogenic agent exposures (control group 2)
Number of subjects: 423
Study: 7787131

Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (gelatin capsules) with a meal (50% fat by calories) immediately following dosing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (gelatin capsules) with a meal (50% fat by calories) at 2 h post-dose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC) with a meal (50% fat by calories) immediately following dosing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC) with a meal (50% fat by calories) at 2 h post-dose
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10 mg dose of 14C-FOX 988 (gelatin capsules)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC)
Number of subjects: 16
Study: 1693797

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 7395685

Group type: EXPERIMENTAL
Intervention: Distraction-free room during structured activity
Number of subjects: 24

Group type: COMPARATOR
Intervention: Distractive room during unstructured activity
Number of subjects: 24
Study: 31971506

Group type: EXPERIMENTAL
Intervention: Namaste Care intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 32
Study: 30650448

Group type: EXPERIMENTAL
Intervention: Free access to an iPad, the Internet, and technical assistance during hospitalization.
Number of subjects: 146
Study: 28366018

Group type: EXPERIMENTAL
Intervention: Narrative smoking education
Number of subjects: 256

Group type: COMPARATOR
Intervention: Informational smoking education
Number of subjects: 256
Study: 25830381

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 50/25 mcg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 100/25 mcg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 200/25 mcg
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 23908486

Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV)
Number of subjects: 2269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2269
Study: 21378714

Group type: EXPERIMENTAL
Intervention: Cytoflavine preparation as energy-correction and antioxidant
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combination of cytoflavine with calcium-D3
Number of subjects: 121
Study: 19255206

Group type: COMPARATOR
Intervention: Nonoperative treatment (28 knees)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Operative treatment (36 knees)
Number of subjects: 71
Study: 17594775

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/calcium-placebo
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/elemental calcium 1000 mg
Number of subjects: 701

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Alendronate-containing treatments
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg with calcium 1000 mg
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 701
Study: 16288620

Group type: EXPERIMENTAL
Intervention: Softseal
Number of subjects: 100

Group type: COMPARATOR
Intervention: LMA-Unique
Number of subjects: 100
Study: 12044254

Group type: EXPERIMENTAL
Intervention: Rapid‐acting anesthetic agents (midazolam, propofol) for refractory status epilepticus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous digital electroencephalogram (EEG) recordings
Number of subjects: 0
Study: 10497778

Group type: EXPERIMENTAL
Intervention: Relapse prevention treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 7697252

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms b.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Budesonide and Placebo
Number of subjects: 30
Study: 2667336

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg before meals
Number of subjects: 9
Study: 973984

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin and Isoniazid in combination
Number of subjects: 0
Study: 31535524

Group type: EXPERIMENTAL
Intervention: Conservative management plus lumbar drain (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative management alone (Group B)
Number of subjects: 60
Study: 29319769

Group type: EXPERIMENTAL
Intervention: Early physiotherapy program from first postoperative day until hospital discharge
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 63
Study: 25805280

Group type: EXPERIMENTAL
Intervention: Video-assisted endoscopy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonendoscopic surgery
Number of subjects: 34
Study: 23571364

Group type: EXPERIMENTAL
Intervention: Copper alloy surfaces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ICU rooms
Number of subjects: 0
Study: 22105039

Group type: EXPERIMENTAL
Intervention: Lady 4 (2 capsules daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19568738

Group type: EXPERIMENTAL
Intervention: Surgical treatment (n = 17)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (n = 15)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 37
Study: 16731088

Group type: EXPERIMENTAL
Intervention: Thorough sonographic oocyte retrieval (n = 34)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine in vitro fertilization retrieval (n = 30)
Number of subjects: 64
Study: 14744726

Group type: EXPERIMENTAL
Intervention: H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Matched placebo (n = 126)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: H. pylori treatment (omeprazole, amoxicillin, clarythromycin)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 248
Study: 11698315

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: i.v. metoclopramide 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study: 9152298

Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal suction (ONPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no ONPS)
Number of subjects: 30
Study: 7899582

Group type: EXPERIMENTAL
Intervention: On-line continuous venovenous hemodiafiltration (OL-CVVHDF)
Number of subjects: 0
Study: 3591496

Group type: EXPERIMENTAL
Intervention: Assertive training (four sessions)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo treatment (career development training sessions)
Number of subjects: 96
Study: 30153988

Group type: COMPARATOR
Intervention: Radial access
Number of subjects: 8404

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 8404

Group type: COMPARATOR
Intervention: Post-procedure bivalirudin infusion
Number of subjects: 8404
Study: 28358599

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg up to 500 mg per day for 4 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 31
Study: 26237812

Group type: EXPERIMENTAL
Intervention: Omnic (tamsulosin) 0.4 mg once daily for 8 years
Number of subjects: 665

Group type: COMPARATOR
Intervention: Herbal preparations (Gentos, Tadenan, or Speman)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Omnic (tamsulosin)
Number of subjects: 665
Study: 23369417

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 21418799

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/benazepril 10 mg once-daily (combination therapy)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Benazepril 10 mg monotherapy
Number of subjects: 220
Study: 18222258

Group type: EXPERIMENTAL
Intervention: CS and VACPB (Group D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: VACPB alone (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CS alone (Group C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No CS and no VACPB (Group A)
Number of subjects: 100
Study: 17018679

Group type: EXPERIMENTAL
Intervention: Community based fire prevention intervention directed to parents, including in-home visits from fire department personnel who installed free lithium smoke detectors and provided a fire escape plan.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 14756429

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy (3 cycles of CEF before and 3 cycles after surgery)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (6 cycles of CEF after primary surgery)
Number of subjects: 101
Study: 11035354

Group type: EXPERIMENTAL
Intervention: One or two digital cervical examinations
Number of subjects: 950

Group type: COMPARATOR
Intervention: No digital cervical examinations
Number of subjects: 950
Study: 8665632

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1, iv over 2-5 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 50
Study: 1410095

Group type: EXPERIMENTAL
Intervention: Severity of illness (depression and anxiety symptoms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychiatric label
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Good or bad psychosocial context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous experience in psychiatry or other vocational training
Number of subjects: 0
Study: 3885850

Group type: EXPERIMENTAL
Intervention: Tobramycin-nafcillin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Shock
Number of subjects: 179
Study: 31721447

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine 2.4 mg/kg weekly
Number of subjects: 82

Group type: COMPARATOR
Intervention: Taxane (docetaxel or paclitaxel)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 82
Study: 28816026

Group type: EXPERIMENTAL
Intervention: 2000-mg sustained-release (SR) acetaminophen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1500-mg sustained-release (SR) acetaminophen
Number of subjects: 14
Study: 27552990

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 140
Study: 24612073

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.75 MAC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1 MAC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.25 MAC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SEF90 and BIS
Number of subjects: 51
Study: 22949381

Group type: COMPARATOR
Intervention: Hair zinc levels in RW group (162.43 ± 91.52 µg/g)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hair selenium levels in RW group (217.37 ± 83.01 µg/g)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Total antioxidant capacity (TAC) in RW group (1.38 ± 0.14 mmol/L)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Number of wheezing episodes in RW group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Number of acute respiratory tract infection (ARTI) episodes in RW group
Number of subjects: 65
Study: 21090334

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 86

Group type: COMPARATOR
Intervention: Medication (metformin 250 mg t.i.d. for 1 week, then 500 mg t.i.d. for 6 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Medication (metformin)
Number of subjects: 86
Study: 18661264

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 3 days with diluted PI eyewash
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 1 day with diluted PI eyewash
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 1 hour with diluted PI eyewash
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Diluted PI eyewash
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Diluted PAI eyewash
Number of subjects: 272
Study: 15897530

Group type: EXPERIMENTAL
Intervention: Rifaximin (200 mg/d, 200 mg twice daily, or 200 mg 3 times daily)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 210

Group type: COMPARATOR
Intervention: Rifaximin and Placebo
Number of subjects: 210
Study: 14719195

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study: 10818278

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ipsapirone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9009402

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1984511

Group type: EXPERIMENTAL
Intervention: Intravenous nimodipine
Number of subjects: 213

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 213
Study: 6635439

Group type: EXPERIMENTAL
Intervention: Parenteral nafcillin plus oral rifampin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Parenteral nafcillin alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rifampin in combination with other oral antibiotics
Number of subjects: 28